IMMUPHARMA PLC — Major Shareholding Notification 2014

Oct 30, 2014

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7093V

Immupharma PLC

30 October 2014

FOR IMMEDIATE RELEASE	30 OCTOBER 2014

NOTIFICATION OF ODEY'S MAJOR INTEREST IN SHARES

Following the Recent Successful £3.4m Fund Raising

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to confirm that  its long standing shareholder Odey Asset Management ("Odey") has increased its shareholding in ImmuPharma Ordinary Shares to 3,433,319 representing a 3.87% shareholding in the Company.

This follows last week's announcement from ImmuPharma that Odey with Aviva plc were lead investors in a £3.4 million fund raising to support the pivotal phase III progress of LupuzorTM, the Company's lead candidate for the treatment of lupus, a potentially life threatening auto-immune disease. 

Commenting on this announcement, Richard Warr, Chairman said: "Odey has been a key investor in ImmuPharma since the Company's inception. We are therefore delighted to have received further support from this major shareholder for our plans to take LupuzorTM through its pivotal Phase III development." 

For further information please see the Group's web site, www.immupharma.com, or contact:

ImmuPharma plc	+ 44 (0) 20 7152 4080
Dimitri Dimitriou, Chief Executive Officer
Dr Robert Zimmer, President and Chief Scientific Officer
Richard Warr, Chairman
Tracy Weimar, Vice President, Operations and Finance
Lisa Baderoon, Head of Investor Relations	+ 44 (0) 7721 413496
Panmure, Gordon & Co., NOMAD & Broker	+44 (0) 20 7886 2500
Hugh Morgan, Fred Walsh, Duncan Monteith

This information is provided by RNS

The company news service from the London Stock Exchange

END

HOLFBLFXZBFBFBK